Campath 1H (Alemtuzumab) Combined With High-Dose Therapy and Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia.

Trial Profile

Campath 1H (Alemtuzumab) Combined With High-Dose Therapy and Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2016

At a glance

  • Drugs Alemtuzumab (Primary) ; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Fludarabine; Melphalan
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 21 Aug 2007 Status change from recruiting to in progress.
    • 11 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top